Etoposide induces cell death via mitochondrial-dependent actions of p53

Cancer Cell International

Vincent Duronio¹  Shu-Huei Tsai¹  Maryam Majd¹  Irene Lam¹  Sarwat Jamil¹ 

[1] Department of Medicine, Jack Bell Research Centre, Vancouver Coastal Health Research Institute, University of British Columbia, 2660 Oak St., Vancouver V6H 3Z6, BC, Canada

关键词: P53 acetylation;    Fibroblast;    DNA damage;    Mitochondria;    Transcription;   

Others  :  1230676
DOI  :  10.1186/s12935-015-0231-z

 received in 2015-05-28, accepted in 2015-07-21,  发布年份 2015

【 摘 要 】

Background

Etoposide has been used clinically in cancer treatment, as well as in numerous research studies, for many years. However, there is incomplete information about its exact mechanism of action in induction of cell death.

Methods

Etoposide was compared at various concentrations to characterize the mechanisms by which it induces cell death. We investigated its effects on mouse embryonic fibroblasts (MEFs) and focused on both transcriptional and non-transcriptional responses of p53.

Results

Here we demonstrate that treatment of MEFs with higher concentrations of etoposide induce apoptosis and activate the transcription-dependent functions of p53. Interestingly, lower concentrations of etoposide also induced apoptosis, but without any evidence of p53-dependent transcription up-regulation. Treatment of MEFs with an inhibitor of p53, Pifithrin-α, blocked p53-dependent transcription but failed to rescue the cells from etoposide-induced apoptosis. Treatment with PES, which inhibits the mitochondrial arm of the p53 pathway inhibited etoposide-induced cell death at all concentrations tested.

Conclusions

We have demonstrated that transcriptional functions of p53 are dispensable for etoposide-induced cell death. The more recently characterized effects of p53 at the mitochondria, likely involving its interactions with BCL-2 family members, are thus more important for etoposide’s actions.

【 授权许可】

   
2015 Jamil et al.

【 图 表 】

Fig.1.

Fig.2.

Fig.3.

Fig.4.

Fig.5.

Fig.6.

【 参考文献 】

• [1]Gudkov AV, Komarova EA. Dangerous habits of a security guard: the two faces of p53 as a drug target. Hum Mol Genet. 2007; 16(Spec No 1):R67-R72.
• [2]Jiang L, Sheikh MS, Huang Y. Decision Making by p53: Life versus Death. Mol Cell Pharmacol. 2010; 2(2):69-77.
• [3]Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994; 54(8):2095-2097.
• [4]Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA et al.. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994; 9(6):1799-1805.
• [5]Zhan Q, Bieszczad CK, Bae I, Fornace AJ, Craig RW. Induction of BCL2 family member MCL1 as an early response to DNA damage. Oncogene. 1997; 14(9):1031-1039.
• [6]Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994; 54(12):3131-3135.
• [7]Speidel D, Helmbold H, Deppert W. Dissection of transcriptional and non-transcriptional p53 activities in the response to genotoxic stress. Oncogene. 2006; 25(6):940-953.
• [8]Johnson TM, Meade K, Pathak N, Marques MR, Attardi LD. Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence. Proc Natl Acad Sci USA. 2008; 105(4):1215-1220.
• [9]Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M et al.. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004; 303(5660):1010-1014.
• [10]Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science. 2005; 309(5741):1732-1735.
• [11]Golubovskaya VM, Cance WG. Targeting the p53 pathway. Surg Oncol Clin N Am. 2013; 22(4):747-764.
• [12]Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV et al.. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999; 285(5434):1733-1737.
• [13]Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I et al.. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol. 2006; 2(9):474-479.
• [14]Leu JI, Pimkina J, Frank A, Murphy ME, George DL. A small molecule inhibitor of inducible heat shock protein 70. Mol Cell. 2009; 36(1):15-27.
• [15]Burden DA, Kingma PS, Froelich-Ammon SJ, Bjornsti MA, Patchan MW, Thompson RB et al.. Topoisomerase II· Etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J Biol Chem. 1996; 271(46):29238-29244.
• [16]Clifford B, Beljin M, Stark GR, Taylor WR. G2 arrest in response to topoisomerase II inhibitors: the role of p53. Cancer Res. 2003; 63(14):4074-4081.
• [17]Jamil S, Mojtabavi S, Hojabrpour P, Cheah S, Duronio V. An essential role for MCL-1 in ATR-mediated CHK1 phosphorylation. Mol Biol Cell. 2008; 19(8):3212-3220.
• [18]Relling MV, Mahmoud HH, Pui CH, Sandlund JT, Rivera GK, Ribeiro RC et al.. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J Clin Oncol. 1996; 14(2):399-404.
• [19]Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, Wolff SN. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res. 1984; 44(1):379-382.
• [20]Minami H, Ando Y, Sakai S, Shimokata K. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J Clin Oncol. 1995; 13(1):191-199.
• [21]Jamil S, Stoica C, Hackett TL, Duronio V. MCL-1 localizes to sites of DNA damage and regulates DNA damage response. Cell Cycle. 2010; 9(14):2843-2855.
• [22]Komarova EA, Gudkov AV. Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors. Biochem Pharmacol. 2001; 62(6):657-667.
• [23]Murphy PJ, Galigniana MD, Morishima Y, Harrell JM, Kwok RP, Ljungman M et al.. Pifithrin-alpha inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation. J Biol Chem. 2004; 279(29):30195-30201.
• [24]Sohn D, Graupner V, Neise D, Essmann F, Schulze-Osthoff K, Janicke RU. Pifithrin-alpha protects against DNA damage-induced apoptosis downstream of mitochondria independent of p53. Cell Death Differ. 2009; 16(6):869-878.
• [25]Gary RK, Jensen DA. The p53 inhibitor pifithrin-alpha forms a sparingly soluble derivative via intramolecular cyclization under physiological conditions. Mol Pharm. 2005; 2(6):462-474.
• [26]Leu JI, George DL. Hepatic IGFBP1 is a prosurvival factor that binds to BAK, protects the liver from apoptosis, and antagonizes the proapoptotic actions of p53 at mitochondria. Genes Dev. 2007; 21(23):3095-3109.
• [27]Wolff S, Erster S, Palacios G, Moll UM. p53’s mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res. 2008; 18(7):733-744.
• [28]Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P et al.. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003; 11(3):577-590.
• [29]Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol. 2004; 6(5):443-450.
• [30]Ubersax JA, Woodbury EL, Quang PN, Paraz M, Blethrow JD, Shah K et al.. Targets of the cyclin-dependent kinase Cdk1. Nature. 2003; 425(6960):859-864.
• [31]Ding H, Duan W, Zhu WG, Ju R, Srinivasan K, Otterson GA et al.. P21 response to DNA damage induced by genistein and etoposide in human lung cancer cells. Biochem Biophys Res Commun. 2003; 305(4):950-956.
• [32]Nilsson I, Hoffmann I. Cell cycle regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res. 2000; 4:107-114.
• [33]Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001; 2(1):21-32.
• [34]Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993; 366(6456):701-704.
• [35]Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene. 2001; 20(15):1803-1815.
• [36]Cliby WA, Roberts CJ, Cimprich KA, Stringer CM, Lamb JR, Schreiber SL et al.. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J. 1998; 17(1):159-169.
• [37]Balaburski GM, Leu JI, Beeharry N, Hayik S, Andrake MD, Zhang G et al.. A modified HSP70 inhibitor shows broad activity as an anticancer agent. Mol Cancer Res. 2013; 11(3):219-229.
• [38]Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E et al.. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 2001; 20(6):1331-1340.
• [39]Olsson A, Manzl C, Strasser A, Villunger A. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ. 2007; 14(9):1561-1575.
• [40]Kobet E, Zeng X, Zhu Y, Keller D, Lu H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc Natl Acad Sci USA. 2000; 97(23):12547-12552.
• [41]Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E et al.. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 2002; 21(22):6236-6245.
• [42]Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem/FEBS. 2001; 268(10):2764-2772.
• [43]Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G et al.. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 1999; 18(7):1805-1814.
• [44]Erster S, Mihara M, Kim RH, Petrenko O, Moll UM. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol. 2004; 24(15):6728-6741.
• [45]Vaseva AV, Moll UM. The mitochondrial p53 pathway. Biochim Biophys Acta. 2009; 1787(5):414-420.
• [46]Ljungman M, Lane DP. Transcription—guarding the genome by sensing DNA damage. Nat Rev Cancer. 2004; 4(9):727-737.